ImpediMed Limited

Equities

IPD

AU000000IPD8

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
0.089 ^AUD	+3.49%		-1.11%	-38.62%

Apr. 17	Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant	MT
Apr. 17	Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16	MT

ImpediMed Limited Announces Resignation of Mrs. Janet West AM as Non-Executive Director

October 02, 2023 at 10:15 pm EDT

ImpediMed Limited announced that Mrs. Janet West AM has resigned as a Non-Executive Director of the Company, effective 2 October 2023. Mrs. West joined the Board on 1 August 2022 and the Board would like to thank Jan for her contribution to the Company during her tenure and wishes her well in the future.

Latest news about ImpediMed Limited

Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant	Apr. 16	MT
Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16	Apr. 16	MT
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting	Apr. 11	CI
ImpediMed Limited(ASX:IPD) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Impedimed Names Independent Non-Executive Chair	Feb. 27	MT
ImpediMed Narrows Loss in Fiscal H1, Revenue Declines; Shares Fall 7%	Feb. 26	MT
Transcript : ImpediMed Limited, H1 2024 Earnings Call, Feb 27, 2024	Feb. 26
ImpediMed Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
ImpediMed Says New Guidelines for Lymphedema Detection Will Help Company Sales	Feb. 14	MT
Transcript : ImpediMed Limited, Q2 2024 Earnings Call, Feb 01, 2024	Jan. 31
Transcript : ImpediMed Limited - Shareholder/Analyst Call	Nov. 29
ImpediMed CEO, CFO Step Down; Shares Fall 11%	Nov. 19	MT
ImpediMed Limited Announces CEO Changes	Nov. 19	CI
ImpediMed Limited Announces CFO Changes	Nov. 19	CI
ImpediMed Limited Announces Management Changes	Nov. 19	CI
ImpediMed Secures Payor Clearance for Spectroscopy Device in the US; Shares Rise 4%	Nov. 02	MT
Transcript : ImpediMed Limited, Q1 2024 Earnings Call, Oct 31, 2023	23-10-30
ImpediMed Limited Announces Resignation of Mrs. Janet West AM as Non-Executive Director	23-10-02	CI
Impedimed Limited Announces Board Changes	23-09-28	CI
Declaration of Voting Results by ImpediMed Limited	23-09-28	CI
ImpediMed Appoints Medical Chief; Shares Down 3%	23-09-26	MT
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer	23-09-26	CI
Transcript : ImpediMed Limited - Special Call	23-09-12
Impedimed Widens Fiscal 2023 Loss; Shares Down 3%	23-08-31	MT
ImpediMed Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI

Chart ImpediMed Limited

Duration

Period

More charts

Company Profile

ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Companyâs SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-29 - March 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for ImpediMed Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.086 AUD

Average target price

0.176 AUD

Spread / Average Target

+104.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
IMPEDIMED LIMITED	-38.62%	113M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+2.21%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology